HPS Pharmacies wish to advise that Perrigo Australia, in consultation with the Therapeutic Goods Administration, (TGA) have given notice of potential safety concern for:
Fentanyl Intranasal Spray 600microgram/2mL
Batch number: E217
Expiry Date: July 2016
This notice has been issued due to one report of a glass fragment being found in a vial of fentanyl intranasal spray 600microgram/2mL from this batch.
No adverse events have been reported and no other batches or presentations of fentanyl intranasal spray are affected by this notice.
In accordance with the recommendations agreed between Perrigo and the TGA, please carefully inspect all stocks of fentanyl intranasal spray (note that the manufacturer named on the label is Orion Laboratories Pty Ltd.). As glass is heavier than water, the vial should be viewed through the base while slowly swirling the solution. Any affected units should be quarantined for return to your supplier. Items supplied by HPS Pharmacies should be returned to the pharmacy for processing.
Retain this notice in a prominent position, including in other related business units until June 2016, when this batch will no longer be in use. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Debra McCready, Perrigo Head of Quality Operations on 0404 137 613.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.